BONNIE S GLISSON to Animals
This is a "connection" page, showing publications BONNIE S GLISSON has written about Animals.
Connection Strength
0.137
-
New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation. Annu Rev Med. 2019 01 27; 70:409-424.
Score: 0.028
-
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res. 2024 Oct 15; 30(20):4743-4754.
Score: 0.011
-
Recurrent small cell lung cancer: update. Semin Oncol. 2003 Feb; 30(1):72-8.
Score: 0.009
-
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 03 08; 39(3):346-360.e7.
Score: 0.008
-
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 05; 9(5):646-661.
Score: 0.007
-
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene. 2018 07; 37(27):3686-3697.
Score: 0.007
-
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017 07 15; 77(14):3870-3884.
Score: 0.006
-
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
Score: 0.006
-
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686.
Score: 0.006
-
Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs. 2015 Sep; 26(8):835-42.
Score: 0.006
-
Combating resistance to anti-IGFR antibody by targeting the integrin ?3-Src pathway. J Natl Cancer Inst. 2013 Oct 16; 105(20):1558-70.
Score: 0.005
-
Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma. Cancer Sci. 2012 Jul; 103(7):1259-66.
Score: 0.004
-
Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation. Int J Cancer. 2012 Nov 15; 131(10):2253-63.
Score: 0.004
-
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012 Aug 15; 118(16):3993-4003.
Score: 0.004
-
Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids. Cancer Chemother Pharmacol. 1992; 31(2):131-8.
Score: 0.004
-
Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther. 2011 Dec; 10(12):2437-48.
Score: 0.004
-
Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase. NCI Monogr. 1987; (4):89-93.
Score: 0.003
-
DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther. 1987; 32(2):89-106.
Score: 0.003
-
Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res. 1986 Apr; 46(4 Pt 2):1934-8.
Score: 0.003
-
Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res. 1986 Apr; 46(4 Pt 2):1939-42.
Score: 0.003
-
Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta. 1984 Oct 05; 783(1):74-9.
Score: 0.003
-
Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. NCI Monogr. 1987; (4):73-8.
Score: 0.001
-
Proliferation dependence of topoisomerase II mediated drug action. Biochemistry. 1986 Apr 22; 25(8):2248-56.
Score: 0.001
-
Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984 Dec; 44(12 Pt 1):5857-60.
Score: 0.001
-
Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res. 1984 Feb; 44(2):626-32.
Score: 0.001